ASX:CU6 Clarity Pharmaceuticals (CU6) Stock Price, News & Analysis → Nvidia’s Quiet $1 Trillion Pivot (From Weiss Ratings) (Ad) Free CU6 Stock Alerts Add Compare Share Share Today's Range N/A50-Day Range N/A52-Week Range N/AVolumeN/AAverage VolumeN/AMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Clarity Pharmaceuticals alerts: Email Address Ad Chaikin AnalyticsLog Into Marc's $5,000 System TodayNew Panic Could Sweep America Mark these words in 2024. Everyone's going to cash… Wall Street legend says: "A little-known vehicle outside of banks could double… triple… or even quadruple your life savings if you know where to find it right now." We urge you to move your cash into this vehicle in 2024. More here. About Clarity PharmaceuticalsClarity Pharmaceuticals Ltd, a clinical stage radiopharmaceutical company, develops theranostic therapy and imaging products for the treatment of cancer in children and adults. Its lead product includes SARTATE, a targeted theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express somatostatin receptor 2. The company is also developing SAR-Bombesin, a pan cancer theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express gastrin releasing peptide receptor; and SAR-bisPSMA, a theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express prostate specific membrane antigen. Clarity Pharmaceuticals Ltd was incorporated in 2010 and is based in Sydney, Australia.Read More Ad Chaikin AnalyticsLog Into Marc's $5,000 System TodayNew Panic Could Sweep America Mark these words in 2024. Everyone's going to cash… Wall Street legend says: "A little-known vehicle outside of banks could double… triple… or even quadruple your life savings if you know where to find it right now." We urge you to move your cash into this vehicle in 2024. More here. CU6 Stock News HeadlinesMay 25 at 10:12 AM | americanbankingnews.comRobert Thomas Purchases 8,333 Shares of Clarity Pharmaceuticals Ltd (ASX:CU6) StockSee More Headlines Receive CU6 Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Clarity Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeASX SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolASX:CU6 CUSIPN/A CIKN/A Webwww.claritypharmaceuticals.com Phone61 2 9209 4037FaxN/AEmployees41Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)A($0.12) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-30,560,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-45.33% Return on Assets-27.67% Debt Debt-to-Equity RatioN/A Current Ratio11.76 Quick Ratio13.19 Sales & Book Value Annual Sales$9.49 million Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book ValueA$0.20 per share Price / BookN/AMiscellaneous Outstanding Shares310,880,000Free FloatN/AMarket CapN/A OptionableNot Optionable Beta1.27 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report Key ExecutivesDr. Alan John Taylor Ph.D.Executive ChairmanDr. Colin David Biggin Ph.D.MD, CEO & Executive DirectorMr. David K. Green BEc.CA, Chief Financial OfficerMr. Shaemus GleasonExecutive Vice President of OperationsDr. Matthew Harris BSc.M.B.A., Ph.D., CTO & Director of TechnologyDr. Jeffrey NorenbergChief Scientific OfficerMichelle ParkerExecutive Vice President of Global Clinical OperationsMr. Robert VickeryCompany SecretaryMore ExecutivesKey Competitors180 Life SciencesNASDAQ:ATNFW3SBioOTCMKTS:TRSBF45525 (CUR.TO)TSE:CUR60 Degrees PharmaceuticalsNASDAQ:SXTPWAbcamOTCMKTS:ABCZFView All CompetitorsInsidersRobert ThomasBought 8,333 shares on 5/20/2024Total: $35,706.91 ($4.29/share)Robert ThomasSold 16,667 sharesTotal: $42,500.85 ($2.55/share)Thomas RamdahlBought 400,000 shares on 3/21/2024Total: $242,000.00 ($0.61/share)Alan TaylorSold 1,764,981 sharesTotal: $1.60 M ($0.90/share) This page (ASX:CU6) was last updated on 5/28/2024 by MarketBeat.com Staff From Our PartnersThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaDigitizing the $11T commodities sector with one tiny stockResource Stock DigestBiggest Prediction of My 50-Year Career on Wall StreetChaikin AnalyticsIs Artificial Intelligence the Biggest Bubble in History?InvestorPlaceExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersHe Is Giving Away BitcoinCrypto Swap Profits41 banks launch ‘crypto dollar’Stansberry Research Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Clarity Pharmaceuticals Ltd Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.